Novo Nordisk has been made aware of some Ozempic® and Saxenda® pens in Uzbekistan, Azerbaijan and Kazakhstan that have been falsified and are not legitimate. The falsified products have been sold both within the legal and illegal supply chain. The content of the falsified pens is entirely different from the genuine products and should not be used as the falsified pens pose a risk to patients’ safety.
The main difference between the counterfeit product and the genuine product is that the genuine Novo Nordisk Ozempic® and Saxenda® pens do not extend or increase in length when setting the dose. The scale drum increments are fixed doses, such as 0.25 mg, 0.5 mg, and 1.0 mg for Ozempic® and 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg for Saxenda®.
A falsified pen can be identified based on scale going from 0 to 80 units and extending out from the pen when setting the dose.
Patient safety is a top priority for Novo Nordisk and we are in close dialogue with all relevant stakeholders to support patients in the best possible way against falsified products.
If you have any questions, please contact firstname.lastname@example.org or call +994124047696.
In case of a severe side effect taking place, seek immediate help from your local hospital or healthcare professional.
If you have experienced a side effect or technical complaint to a Novo Nordisk product, we encourage you to also report this to Novo Nordisk.
All medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints. By monitoring quality and safety information on our products, we can take due and appropriate actions to safeguard patient safety.
Fulfilling its responsibilities in the field of pharmacovigilance, the company asks doctors and patients to report all cases of adverse events and technical complaints observed with the use of Novo Nordisk products. The message will be processed by the Pharmacovigilance Specialist.
Telephone number: +994 12 404 76 96